New pill aims to tame dangerous phosphate in kidney patients
NCT ID NCT07285304
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 study tests a new drug called TS-172 in 300 adults on hemodialysis who have high phosphate levels. Participants take the pill daily for up to a year to see if it safely and effectively controls phosphate. The goal is to offer a better treatment option for a common complication of kidney failure.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TS-172 (a phosphate binder taken orally)
- What this could lead to
- If it works, this could offer a new option to help dialysis patients better manage high phosphate levels, reducing complications.
- What could go wrong
- This is a long-term safety study, so it may not show clear benefit. Side effects or lack of effectiveness could limit its use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Taisho Pharmaceutical Co., Ltd selected site
RECRUITINGTokyo, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Aging kidneys under the microscope: could a simple test predict failure?
- Could your gut bacteria hold the key to protecting your kidneys?
- Food as medicine: could cooking classes slow kidney disease?
- Could a phone app be the key to managing kidney disease?
- A new pill aims to slow kidney failure and save lives
- AI takes on kidney disease: a new model to forecast Who's at risk